Abstract

In order to clarify the pathological involvement of the sympathetic nervous system in the development of cardiomyopathy, a receptor-binding study was carried out on cardiomyopathic Syrian hamsters of strain BIO 14.6 (BIO) at 21 days (prenecrotic stage); 35-42 days (onset of cardiomyopathy); and 70-84 days of life (early cardiac hypertrophy). The newly developed alpha 1-blocker (bunazosin hydrochloride) was initially administered at doses of 100 micrograms/kg or 10 mg/kg to BIO hamsters at 21 days of life and continued for 70 days. At the onset of cardiomyopathy and early cardiac hypertrophy, there was an increase in the number of alpha 1-receptors in the BIO hamsters compared to controls, but there were no significant changes at the prenecrotic stage. On histopathological examination, 10 mg/kg bunazosin had a significant beneficial effect on cardiomyopathy [area of necrosis 1.38% in untreated vs 0.33% in treated animals; area of calcification 2.70% (untreated) vs 0.60% (treated); area of all myocardial injuries 6.97% (untreated) vs 3.19% (treated)]. However, 100 micrograms/kg bunazosin had no effect. It was concluded that the increase in the number of alpha 1-receptors may not be involved in the pathogenesis of cardiomyopathy but that alpha 1-receptors could be implicated in the later progression of the condition.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.